• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

2cureX

1.82 SEK

-3.19 %

Less than 1K followers

2CUREX

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Compare
-3.19 %
-2.46 %
+67.16 %
+254.47 %
+144.24 %
-48.82 %
-58.50 %
-88.66 %
-76.05 %

2cureX is a Danish-based biotech company with subsidiary in Hamburg, Germany. The company has made a special sensitivity test, IndiTreat, for oncology clinics that is focused on improving the outcome for cancer patients by improving the efficiency of the individual cancer treatment. IndiTreat uses a biopsy from the individual cancer patient to measure and predict the likely outcome of different available treatments, thereby assisting oncologists to choose the most effective treatment for the individual patient.

Read more
Market cap
58.13M SEK
Turnover
10.48K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
25.6
2026

General meeting '26

27.8
2026

Interim report Q2'26

4.3
2027

Annual report '26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release25.06.2026, 18.00

The Directed Issue announced 22 April 2026 will be registered at Bolagsverket under the authorization granted by the Annual General Meeting held on 25 June 2026.

2cureX
Regulatory press release25.06.2026, 15.00

Communiqué from the Annual General Meeting on Thursday 25 June 2026 in 2cureX AB

2cureX
Regulatory press release28.05.2026, 18.10

THIS PRESS RELEASE IS AN ENGLISH TRANSLATION OF THE LEGALLY BINDING SWEDISH PRESS RELEASE: “PUBLICERING AV ÅRSREDOVISNINGEN FÖR 2CUREX AB (publ)”.

2cureX

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release25.05.2026, 22.45

Correction: Notice of annual general meeting in 2cureX AB

2cureX
Regulatory press release25.05.2026, 14.30

Notice of annual general meeting in 2cureX AB

2cureX
Regulatory press release20.05.2026, 16.45

2cureX AB Expands Functional Precision Medicine Infrastructure Through Strategic Collaboration with StoreMyTumor

2cureX
Regulatory press release19.05.2026, 20.05

2cureX AB’s Executive Management is pleased to invite shareholders and investors to a live webcast and business update on 20 May at 7pm CET.

2cureX
Regulatory press release22.04.2026, 09.25

2cureX AB completes oversubscribed directed issue

2cureX
Regulatory press release26.02.2026, 19.30

2cureX AB (publ) publishes Interim Report for the Second Half of 2025

2cureX
Press release29.08.2025, 13.40

CEO Nathaniel Hutley presents a strategic update on 2cureX’s new Website Blog.

2cureX
Regulatory press release21.08.2025, 16.10

2cureX AB (“2cureX”) hereby publishes the interim report for the first half year of 2025.

2cureX
Press release11.07.2025, 21.10

Improved communication from 2cureX AB

2cureX
Press release02.07.2025, 13.19

Correction: CEO Nathaniel Hutley presents latest news from 2cureX on July 2nd 2025.

2cureX
Press release01.07.2025, 14.25

2cureX AB is in the process of securing a strategic collaboration with PreComb Therapeutics AG.

2cureX
Press release13.06.2025, 14.15

CEO Nathaniel Hutley presents latest news from 2cureX on July 2nd 2025.

2cureX
Regulatory press release30.05.2025, 13.30

NOTICE OF ANNUAL GENERAL MEETING OF 2CUREX AB (publ).

2cureX
Regulatory press release29.05.2025, 17.30

RELEASE OF THE 2CUREX AB (PUBL) ANNUAL REPORT

2cureX
Regulatory press release22.05.2025, 09.15

2cureX appoints Mangold Fondkommission AB as new Certified Adviser

2cureX
Press release20.05.2025, 10.00

2cureX Conducts First Direct-to-Patient IndiTreat® Test Under “Operation Twin Code” Strategy

2cureX
Regulatory press release15.05.2025, 17.20

2cureX AB (2CUREX) Launches “Operation Twin Code” with New Investors, Leadership Transition, and Global Roadmap

2cureX